Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

Biotechnology company Moderna (NASDAQ:MRNA) announced better-than-expected revenue in Q2 CY2025, but sales fell by 41.1% year ...

The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...

Moderna (MRNA) stock drops even after beating Q2 2025 forecasts, as it lowered the top end of the revenue outlook due to vaccine shipment delays. Read more here.

Nevertheless, Moderna has lowered its revenue guidance for the year by $300 million. The company now expects to generate ...

Just one day after CEO Stéphane Bancel’s sudden announcement of a 10% workforce reduction, Moderna has released Q2 2025 that ...

Moderna beat Q2 earnings and revenue estimates, narrowed its annual forecast, won a key patent case, and plans to cut 10% of its global workforce.

Q2 2025 Earnings Call Transcript August 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.13, ...

Despite a net loss, Moderna Inc (MRNA) showcases resilience with significant cost cuts, new FDA approvals, and a robust cash ...

Despite efforts to spare employees by scaling back R&D and reducing operating costs by roughly $1.5 billion over the next two years, it appears Moderna’s previous cost-cutting efforts haven’t g | ...

It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough programs on its hands.